Q1 EPS Estimates for Nuvectis Pharma Lowered by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities researchers at Roth Capital dropped their Q1 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a research report issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($0.28) per share for the quarter, down from their previous forecast of ($0.23). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.12) EPS and FY2027 earnings at $1.33 EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Separately, HC Wainwright cut their target price on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th.

Nuvectis Pharma Price Performance

NVCT stock traded up $0.20 during midday trading on Friday, reaching $6.34. The company had a trading volume of 69,970 shares, compared to its average volume of 113,269. The firm has a 50-day moving average price of $6.34 and a 200-day moving average price of $6.41. The company has a market capitalization of $148.31 million, a P/E ratio of -5.47 and a beta of 0.22. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $12.10.

Remove Ads

Institutional Trading of Nuvectis Pharma

Several institutional investors have recently added to or reduced their stakes in NVCT. Squarepoint Ops LLC bought a new stake in shares of Nuvectis Pharma in the 4th quarter valued at about $103,000. Cubist Systematic Strategies LLC bought a new stake in Nuvectis Pharma in the fourth quarter valued at approximately $34,000. Northern Trust Corp boosted its stake in shares of Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company's stock valued at $139,000 after purchasing an additional 10,472 shares during the period. Marshall Wace LLP boosted its stake in shares of Nuvectis Pharma by 191.0% during the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock valued at $674,000 after purchasing an additional 81,757 shares during the period. Finally, Baxter Bros Inc. grew its holdings in shares of Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock worth $81,000 after purchasing an additional 2,500 shares during the last quarter. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 240,000 shares of Nuvectis Pharma stock in a transaction that occurred on Friday, February 7th. The shares were bought at an average price of $5.00 per share, with a total value of $1,200,000.00. Following the acquisition, the insider now owns 2,884,121 shares in the company, valued at approximately $14,420,605. This trade represents a 9.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have bought 261,500 shares of company stock worth $1,300,825. 35.78% of the stock is currently owned by insiders.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.